Important Therapy Provides Six Months Pain Relief with Single Injection CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the U.S. Food and Drug Administration ...

Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...

CAMBRIDGE, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has received a letter from the U.S. Food and Drug Administration requesting ...

GAITHERSBURG, Maryland (Reuters) - A U.S. advisory panel has unanimously backed a new version of a Genzyme Corp injection to relieve knee pain from osteoarthritis. The panel of experts voted 5-0 on ...

A federal panel of advisers Tuesday voted unanimously in favor of approval of Genzyme Corp.'s Synvisc-One, an investigational injectable product intended to relieve pain associated with osteoarthritis ...

Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...

To earn CME related to this news article, click here. March 5, 2009 — The US Food and Drug Administration (FDA) has approved budesonide plus formoterol fumarate dihydrate inhalation aerosol for the ...

Please provide your email address to receive an email when new articles are posted on . Sanofi has issued a limited voluntary recall of its Synvisc-One, an injected gel for treating arthritis, due to ...

CAMBRIDGE, Mass. Genzyme, a biotech company has announced that the Food and Drug Administration has delayed the release of the company’s new osteoarthritis drug, Synvisc-One because, the agency wants ...